Thursday May 25th 2017

Archive for March, 2017

​Biogen wins another big Tecfidera patent case

​Biogen wins another big Tecfidera patent case

For the second time in as many weeks, Biogen has prevailed in a high-stakes legal dispute over patents on its blockbuster multiple sclerosis treatment Tecfidera. The U.S. Patent Trial and Appeal Board on Friday rejected a bid by Danish biotech Forward Pharma (Nasdaq: FWP) [Read More]

U.S. judge invalidates Acorda multiple sclerosis drug patents

U.S. judge invalidates Acorda multiple sclerosis drug patents

(Reuters) - A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted. (Source: Reuters: Health) [Read More]

Immuno-fluorescence in 3-D

Immuno-fluorescence in 3-D

Potent Markers! We are seeing more3-D Cell Based Assays being used for Neuroscience Research. It is important researchers have theNeuron-Astroglial-Progenitor Markers required for staining in 3-D. This helps researchers determine the cell types present in their assays.I [Read More]

 Page 1 of 37  1  2  3  4  5 » ...  Last » 

Latest Topics

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Hospitals vary widely in how often they transition people with strokes from active treatment to comfort or hospice care [Read More]

Roche investigating case of patient illness after taking MS drug

Roche investigating case of patient illness after taking MS drug

ZURICH (Reuters) - A person in Germany treated with Roche ’s new multiple sclerosis drug Ocrevus has been diagnosed [Read More]

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]